Joanna Grabska, MD
Hematology & Oncology · Greenville, SCNPI 1144546557
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $896 of the $1,126 with a category attached, or 79.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $256 and has fallen 63.7% since, to $93 in 2025. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 45 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$206
- Astrazeneca UK Limited$135
- Regeneron Healthcare Solutions, Inc.$118
- Pfizer$75
- Taiho Oncology, Inc.$73
- Boston Scientific$63
- plus $455 from 17 others
Across 3 payments — averaging $6893.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$21K
What the payments were for
- Food & beverage$89680%
- Education$23020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 3 | $206 |
| Astrazeneca UK Limited | 1 | $135 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Pfizer | 6 | $75 |
| Taiho Oncology, Inc. | 4 | $73 |
| Boston Scientific | 1 | $63 |
| Tersera Therapeutics LLC | 3 | $58 |
| Gilead | 3 | $55 |
| Bristol Myers Squibb | 3 | $49 |
| Genentech USA, Inc. | 3 | $40 |
| Bayer | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Daiichi Sankyo Inc. | 1 | $28 |
| AbbVie | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Verastem, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,126 in reported general payments places this provider in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $536,004 |
| TagrissoOsimertinib Mesylate | 12 | $205,755 |
| Pazopanib Hcl | 12 | $180,254 |
| XareltoRivaroxaban | 40 | $29,080 |
| EliquisApixaban | 22 | $24,950 |
| Letrozole | 221 | $5,456 |
| Anastrozole | 151 | $3,140 |
| Exemestane | 39 | $2,946 |
| Tamoxifen Citrate | 77 | $1,927 |
| Mirtazapine | 13 | $470 |
| Potassium Chloride | 25 | $339 |
| Hydroxyurea | 13 | $307 |
| Prochlorperazine Maleate | 14 | $270 |
| Duloxetine Hcl | 19 | $229 |
| Ondansetron Hcl | 19 | $222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $75 | $560,95456 claims |
| Johnson & JohnsonXarelto | $17 | $29,08040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Elizabeth CullGreenville$16K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.